Displaying drugs 2251 - 2275 of 3033 in total
CIGB-258 peptide
CIGB-258 is a peptide that is immunoregulatory and derived from heat shock protein 60 of the cellular variant. As of 2020, The Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba, is testing the treatment efficacy of this peptide in patients with COVID-19 who are under intensive therapy regimens...
Investigational
Matched Description: … As of 2020, The Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba, is testing the …
Lulizumab pegol
Lulizumab pegol is under investigation in clinical trial NCT02843659 (Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome).
Investigational
Histidine
An essential amino acid that is required for the production of histamine.
Investigational
Nutraceutical
Matched Salts cas: … 13870-80-9 …
Matched Mixtures name: … Aminosyn II 7% With 50% Dextrose ... Aminosyn II 8.5% With 50% Dextrose ... VAMIN 9 EF ELEKTROLITSIZ AMINOASİT SOLÜSYON, 500 ML …
Matched Mixtures name: … Aminosyn II 7% With 50% Dextrose ... Aminosyn II 8.5% With 50% Dextrose ... VAMIN 9 EF ELEKTROLITSIZ AMINOASİT SOLÜSYON, 500 ML …
Alanine
Alanine is a non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system.
Nutraceutical
Matched Mixtures name: … Aminosyn II 7% With 50% Dextrose ... Aminosyn II 8.5% With 50% Dextrose ... VAMIN 9 EF ELEKTROLITSIZ AMINOASİT SOLÜSYON, 500 ML …
Arginine
An essential amino acid that is physiologically active in the L-form.
Investigational
Nutraceutical
Matched Mixtures name: … Aminosyn II 7% With 50% Dextrose ... Aminosyn II 8.5% With 50% Dextrose ... VAMIN 9 EF ELEKTROLITSIZ AMINOASİT SOLÜSYON, 500 ML …
Sparteine
Sparteine is a plant alkaloid derived from Cytisus scoparius and Lupinus mutabilis which may chelate calcium and magnesium. It is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents. Sparteine is not currently FDA-approved for human use, and its salt, sparteine sulfate, is one...
Experimental
Withdrawn
Methyl-D9-choline
Methyl-D9-choline is under investigation in clinical trial NCT01807910 (ER Stress in NAFLD).
Investigational
L-Dilinoleoyllecithin
Experimental
Tegavivint
Investigational
Matched Iupac: … N-[2,7-bis({[(3R,5S)-3,5-dimethylpiperidin-1-yl]sulfonyl})-10-(hydroxyimino)-9,10-dihydroanthracen-9- …
Coronavirus-Like Particle COVID-19 Vaccine
The Coronavirus-Like Particle COVID-19 Vaccine is in development and testing through Meidcago in Quebec City, Canada. The vaccine was developed by creating SARS-Cov-2 virus-like particles (CoVLPs), which mimic the structure of the virus without carrying the genetic components required for infection. VLPs are thought to have multiple mechanisms involving the...
Investigational
Matched Description: … In July 2020, Medicago partnered with Dynavax to test the vaccine with its adjuvant, Cpg 1018 (also known ... A Phase 1 clinical trial was launched in July 2020 evaluating the safety, tolerability, and immunogenicity …
Fluperolone
Experimental
Deutivacaftor
Deutivacaftor is under investigation in clinical trial NCT03227471 (A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis).
Investigational
Lithium cation
Lithium was used during the 19th century to treat gout. Lithium salts such as lithium carbonate (Li2CO3), lithium citrate, and lithium orotate are mood stabilizers. They are used in the treatment of bipolar disorder, since unlike most other mood altering drugs, they counteract both mania and depression. Lithium can also...
Experimental
KRN-5500
KRN-5500 is under investigation in clinical trial NCT00002923 (KRN5500 in Treating Patients With Metastatic Solid Tumors).
Investigational
BBIBP-CorV
BBIBP-CorV vaccine contains a SARS-CoV-2 strain inactivated inside Vero Cells. Investigation shows this vaccine induces neutralizing antibodies in several mammalian species while also showing protective efficacy with SARS-CoV-2 challenge in rhesus macaques . As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.
Investigational
Matched Description: … As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials …
V591
The V591 vaccine, part of Merck’s COVID-19 vaccine programming, was developed using a modified measles vaccine virus as a vector for COVID-19 antigen delivery . Through Merck’s acquisition of Thermis in May 2020, they were able to leverage Thermis’ platform knowledge and accelerate the development of V591 to phase I...
Investigational
Matched Description: … Through Merck’s acquisition of Thermis in May 2020, they were able to leverage Thermis’ platform knowledge …
Semorinemab
Semorinemab is under investigation in clinical trial NCT03289143 (A Study to Evaluate the Efficacy and Safety of RO7105705 in Patients With Prodromal to Mild Alzheimer's Disease).
Investigational
Dimetacrine
Dimetacrine is also known as dimethacrine or acripamine. It is marketed under the names Istonil, Istonyl, Linostil, and Miroistonil. Dimetacrine is a tricyclic antidepressant (TCA) with imipramine-like effects used in Europe for the treatment of depression. Dimetacrine is no longer used in Japan.
Experimental
Withdrawn
CVnCoV
The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body. As of June 2020, the company received regulatory approval from German and Belgian Authorities...
Investigational
Matched Description: … As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence …
BNT162b3
The BNT162b3 vaccine is the latest addition to BioNTech and partner Pfizer’s mRNA COVID-19 vaccine program. Similar to BNT162b2, BNT162b3 uses a nucleoside-modified RNA (modRNA) technology. Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate further testing of it. As such, BNT162b3 has...
Investigational
Matched Description: … As such, BNT162b3 has entered a phase I/II study in early September 2020 (NCT04537949). …
XL281
XL281 is a novel anticancer compound designed to potently inhibit the RAS/RAF/MEK/ERK signaling pathway. Mutational activation of RAS occurs in about 30 percent of all human tumors, including non-small cell lung, pancreatic, and colon cancer. XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which...
Investigational
Matched Description: … form of B-RAF, which is activated in 60 percent of melanomas, 24-44 percent of thyroid cancers, and 9 …
Technetium Tc-99m epratuzumab
Technetium Tc-99m epratuzumab is under investigation in clinical trial NCT00003337 (Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma).
Investigational
Displaying drugs 2251 - 2275 of 3033 in total